A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry

Therapeutic Drug Monitoring

Volumn 37, Issue 2, 2015, Pages 220-228

  Amara, Alieu B ^a   Else, Laura J ^a   Tjia, John ^a   Olagunju, Adeniyi ^a,b   Puls, Rebekah L ^c   Khoo, Saye ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

blood plasma ratio; dried blood spots; efavirenz; liquid chromatography mass spectrometry; pharmacokinetics

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STABILITY; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MEASUREMENT ACCURACY; PRIORITY JOURNAL; BLOOD; CALIBRATION; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HIV INFECTIONS; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; VALIDATION STUDY;

ANTI-HIV AGENTS; BENZOXAZINES; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HIV INFECTIONS; HUMANS; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS;

EID: 84925862510     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000127     Document Type: Article

References (33)

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2013.
2. World Health Organisation. Consolidated guidelines on the use of anti-retroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 1st Edition. Geneva, Switzerland: World Health Organization. 2013.
3. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358-1361.
4. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47: 130-137.
5. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
6. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
7. ENCORE1 Study Group. A daily dose of 400mg efavirenz (EFV) is noninferior to the standard 600mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial in HIV-infected, antiretroviral-naive adults. Lancet. 2014;383: 1474-1482.
8. Guthrie R, Susi A. A simple phenylalanine method for detecting phenyl-ketonuria in large populations of newborn infants. Pediatrics. 1963;32: 338-343.
9. Ter Heine R, Hillebrand MJ, Rosing H, et al. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chro-matography tandem mass spectrometry. J Pharm Biomed Anal. 2009; 49:451-458.
10. ter Heine R, Rosing H, van Gorp EC, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrom-etry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867: 205-212.
11. Meesters RJ, van Kampen JJ, Reedijk ML, et al. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Anal Bioanal Chem. 2010;398:319-328.
12. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31:327-336.
13. Koal T, Burhenne H, Romling R, et al. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19: 2995-3001.
14. Ter Heine R, Mulder JW, van Gorp EC, et al. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegra-vir and ritonavir in dried blood spot samples. Bioanalysis. 2011;3: 1093-1097.
15. Kromdijk W, Mulder JW, Rosing H, et al. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother. 2012;67:1211-1216.
16. Kromdijk W, Mulder JW, Smit PM, et al. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antivir Ther. 2013;18:821-825.
17. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2:1385-1395.
18. Orsini JJ, Yeman J, Caggana M, et al. Semi-quantitative method for determination of hematocrit in dried blood spots, using data collected in HPLC hemoglobin variant testing. Clin Chim Acta. 2010;411: 894-895.
19. Youhnovski N, Bergeron A, Furtado M, et al. Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun Mass Spectrom. 2011;25: 2951-2958.
20. Holub M, Tuschl K, Ratschmann R, et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta. 2006;373:27-31.
21. Antony SJ, Harrell V, Christie JD, et al. Clinical differences between pulmonary and extrapulmonary tuberculosis: a 5-year retrospective study. J Natl Med Assoc. 1995;87:187-192.
22. FDA. Guidance for industry, bioanalytical method validation. US Food and Drug Administration. 2001. Available at: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed July 2, 2014.
23. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
25. Health Protection Agency. Quality assurance in the diagnostic virology and serology laboratory. UK Standards for Microbiology Investigations. 2011;Q2:Available at: http://www.hpa.org.uk/SMI/pdf. Accessed July 2, 2014.
26. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretro-viral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291.
27. Adam BW, Alexander JR, Smith SJ, et al. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem. 2000;46:126-128.
28. Wickremsinhe ER, Huang NH, Abdul BG, et al. Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles. Bioanalysis. 2013;5:159-170.
29. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 2010;12:290-293.
30. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19:825-835.
31. Almond LM, Hoggard PG, Edirisinghe D, et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 2005;56:738-744.
32. Hoffman JT, Rossi SS, Espina-Quinto R, et al. Determination of efavir-enz in human dried blood spots by reversed-phase high-performance liquid chromatography with UV detection. Ther Drug Monit. 2013;35: 203-208.
33. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24:49-65.